# Step 242 — PC04.06 implementation readiness and unresolved dependencies

2026-10-29 (America/Toronto). **Implementation completed: NO — required source and clinical contracts remain unresolved. PC04.06 remains pending / BLOCKED for implementation, not SATISFIED.** Recorded the requested Step 241 manual evidence and verified the exact requirement against the retained source extraction and current prescribing boundaries. No application, database or service change was made. Inventory remains **7 IDs / 3 packages**.

## 1. Branch and worktree preservation

Inspected the current branch/worktree, then safely created the owner-requested local branch **`feature/step-242-pc04-06`** from `main` at the same HEAD. Carried all existing work intact: the modified manifest, corrected DPD adapter/tests, Web partial-path fix and untracked reports 308–313. No commit, push, pull, fetch, merge, rebase, reset, clean or stash occurred.

Only these files were added by Step 242:

- `docs/certification/314-step241-pc04-01-dpd-manual-verification.md`.
- `docs/certification/315-step242-pc04-06-implementation.md`.

The Step 241 report clearly attributes authenticated UI, `tyl`, `ACETAMINOPHEN`, exact DIN `02039990` and product-detail results to the owner. No DPD investigation, deployment, authentication or catalogue testing was repeated. PC04.01 remains PARTIAL; DE09.032 was not reopened.

## 2. Exact PC04.06 requirement and source

Source: [Primary Care Baseline — 1.7 Requirements.pdf](</D:/MasterProgram_Ahmed/Ontario EMR Specification/Functional/Primary Care Baseline - 5.5 Final - 2026-05-04/Primary Care Baseline - 1.7 Requirements.pdf>), **Document Version 1.7 Final, March 20, 2026, §2.4 Medication Management, printed pages 18–19, PC04.06, mandatory M**.

> The EMR Offering MUST perform drug-to-drug interaction using a publicly available COTS drug database with Canadian drug codes.

Relevant guidelines require the EMR to indicate severity and allow override for each identified interaction, trigger interactions only for **active prescriptions**, and obtain severity from **COTS**. The retained mapping also records that an open-source solution lacking licensing, support and maintenance provisions is not accepted.

Read the existing source extracts `.tmp/step185/page-18.txt` and `page-19.txt` and reused [Step 185 §2](261-step185-remaining-mandatory-gap-prioritization.md), [Step 45's PC04 mapping](77-step45-baseline-1.7-reconciliation.md) and [Step 190's PC04.06 dependency row](266-step190-independent-gap-implementation-assessment.md). The older primary-care PC04 matrix predates authoritative recovery and is not the controlling requirement source. No repository-wide assessment or supplier research was performed. Retain the existing folder-version/document-version and release-applicability qualifications.

## 3. Existing implementation evidence

Scoped inspection confirms reusable foundations:

- `src/MicroEMR.Application/PatientPrescriptions/PatientPrescriptionModels.cs`: prescription identities, dates, structured drug identifiers, history/lifecycle DTOs, Draft validation/catalogue selection and existing finalize/cancel boundaries. Status values are Draft, Finalized, Cancelled and Superseded; these lifecycle values do not independently define active treatment.
- `src/MicroEMR.Application/DrugCatalog/DrugCatalog.cs`: Canadian DIN/product identity, ingredients, strength, form, route, source metadata and selected-product validation. These are product facts, not drug-pair interaction knowledge or supplier interaction severity.
- `src/MicroEMR.Application/Cds/CdsServices.cs`, `CdsModels.cs` and `DependencyInjection.cs`: generic rule registry/evaluation and alert acknowledgement/dismissal infrastructure. Generic Info/Warning categories and dismissal reasons are not a supplier severity/override contract. The retained empty-production-rule finding remains consistent with the inspected registration boundary.
- `src/MicroEMR.Api/Controllers/PatientPrescriptionsController.cs`: existing authenticated patient-scoped prescribing operations, `PrescriptionsPrescribe` permission, version/lifecycle checks and actor handling. No supplier interaction check/override path is integrated at the inspected prescribing boundary.

Reuse the retained native prescription tenant/actor, original-prescriber, stored-procedure audit, concurrency, correction and immutable-artifact evidence. Those controls were not retested or claimed as new PC04.06 acceptance evidence.

## 4. Functional gap and implementation gate

| Area | Missing behavior / decision |
| --- | --- |
| Interaction knowledge | A designated licensed/supportable Canadian-coded interaction source, usable API/data contract, permitted development access and maintained release provenance |
| Identity / severity | Supplier product/substance mapping and actual supplier severity codes/labels; handling of manual or unmapped prescriptions |
| Active prescriptions | An approved rule for treatment activity, date precision/unknowns, stopped/completed treatment and relevant existing prescriptions; Finalized or catalogue MARKETED must not be substituted for patient treatment activity |
| Clinical trigger / failures | Approved check timing, source-unavailable/unmapped/incomplete outcomes and response to changed prescription/source inputs |
| UI / override | Display each real interaction and its supplier severity, and allow clinician override under an approved workflow; reason requirements and warning/blocking behavior remain policy decisions |
| Persistence / audit | Bind check results and overrides to tenant, patient, prescription/input versions, supplier/source version, interaction identity, actor and time, with concurrency and clinical audit; exact schema awaits the real contract |
| Permissions / isolation | Extend existing prescribing authorization and patient/tenant context; no decision to add or change roles or override permissions has been approved |
| Print / output | PC04.06's cited text does not mandate a new printed output. No unrelated prescription-print change is justified |

These are the same substantive dependencies retained in Steps 185/190. The Step 241 DPD checkpoint resolves catalogue development verification; it supplies no interaction dataset, severity taxonomy or approved clinical policy. The task permits implementation when sufficiently established. That gate is not met for a smallest complete production change.

No fabricated drug pairs, guessed severity scale, free-text matching, settings-only screen or placeholder provider was added. A synthetic mechanics test would not establish the required clinical behavior. No application source or configuration was changed.

## 5. Database, permissions, audit and isolation

**Database changes made: NONE. Migration added/applied: NONE.** No persistent or disposable database was accessed. The approved future persistent target remains `EC2AMAZ-TC26CQK\TELEMED52` / `MicroEMR_LocalDev_Fresh` / `local-dev-fresh`; it was not reverified because no database operation was needed.

Future durable check/override records will require a contract-specific persistence design, stored-procedure writes and audit coverage; no schema is justified before the source and workflow contract is established. Persistent deployment would require explicit authorization for the specific operation.

No permission, authentication, patient/clinical record, finalized artifact or historical record was changed. Web, API and Auth were not restarted. Existing authorization/tenant/patient controls were preserved; new PC04.06 override audit and isolation coverage is **not implemented or verified**.

## 6. Focused verification and preservation checks

**Automated Application/Infrastructure/API tests: NOT RUN (0 executed). Build/typecheck: NOT RUN.** Only documentation changed, and there is no new functional implementation to test. No passing test count or PC04.06 clinical acceptance is claimed.

Performed focused document/source checks: exact requirement/guideline mapping; prescribed existing-code boundaries; report/inventory consistency; protected-file hash comparison and diff/whitespace review. Pre-existing tracked changes and reports 308–313 remained unchanged. No broad tests or previously completed certification tests were repeated.

After implementation is unblocked, focused verification must cover real source identity/severity mapping, active/inactive inputs, per-interaction override, source failures/unknown outcomes, changed/stale inputs, auditable decision persistence, permitted/denied actors and tenant/patient isolation. Manual clinician acceptance must verify warning presentation, supplier severity and override in the approved workflow. These are future checks, not results of Step 242.

## 7. Status and mandatory inventory

**PC04.06 — pending / BLOCKED for implementation by unresolved source and clinical contracts.** The missing functional behavior remains missing. No formal OntarioMD approval or SATISFIED status is claimed.

| Package | Mandatory ID | Status |
| --- | --- | --- |
| Prescribing | PC04.01 | PARTIAL; commercial COTS qualification unresolved |
| Prescribing | PC04.06 | Pending; implementation blocked as documented above |
| Prescribing | PC04.07 | Pending |
| Prescribing | PC04.09 | Pending |
| Prescribing | PC04.14 | Pending |
| CPP | PC07.01 | PARTIAL |
| Scheduling | PC09.03 | Pending |

**Remaining: 7 IDs / 3 packages.** No other requirement was silently closed or reassessed.

## 8. Recommended Step 243

Resolve the bounded PC04.06 implementation contract: identify an existing licensed Canadian-coded interaction source and provide its permitted development API/data schema and supplier severity contract; approve active-prescription inputs, trigger timing, unavailable/unmapped behavior and clinician override policy. Reuse the established prescribing controls and DPD development evidence. Once those inputs exist, implement the actual supplier-backed check and audited override path with focused tests. No PC04.01 reopening, additional catalogue acceptance, clinical mutation, service restart or persistent migration is required merely to settle that contract.
